Market news

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.

Olema Pharmaceuticals (NASDAQ:OLMA) shares fell 15. 1% in pre-market trading to $8.

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.

SAN FRANCISCO, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage...

SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced the appointment of Jason O’Byrne, MBA, as Chief Financial Officer. “We are very pleased to welcome Jason to Olema at an important time for the Company,” said Sean P. Bohen, M.D., Ph.D., President and Chief

Olema Pharmaceuticals (OLMA) said Thursday it has appointed Jason O'Byrne as its chief financial off

Olema Pharmaceuticals shares fall after completing OPERA-01 Phase 3 enrollment, with top-line data now expected in Q1 2027.

Olema Pharmaceuticals (OLMA) reported a Q2 net loss late Monday of $0.61 per diluted share, widening

SAN FRANCISCO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to seven new employees to purchase an aggregate of 254,540 shares of the Company's common stock, effective as of August 3, 2026. These awards were approved by the Comp